Latest Quinazolines Stories
- Results from two large trials individually showed an improvement in the secondary endpoint of overall survival for patients with the most common EGFR mutation (Del19) RIDGEFIELD, Conn., Jan.
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
The Oncology Institute of Hope and Innovation is pleased to announce the recent openings of clinical trials this holiday season. Downey, CA (PRWEB) November
Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports
However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
New research report “Global Cancer Kinase Inhibitors Market & Pipeline Insight” elaborated by Kuick Research is now available at MarketPublishers.com.
Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients SAN DIEGO, Sept.
- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing
- To fire mitraille at.